In Vitro evaluation of the activity of gemcitabine-loaded pegylated unilamellar liposomes against papillary thyroid cancer cells

Open Drug Delivery Journal

Volumn 4, Issue , 2010, Pages 55-62

  Vono, Margherita ^a   Cosco, Donato ^a   Celia, Christian ^a   Paolino, Donatella ^a   Celano, Marilena ^a   Russo, Diego ^a   Fresta, Massimo ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Anticancer drug delivery; Cell culture; Gemcitabine; In vitro antiproliferative activity; Papillary thyroid carcinoma; Pegylated unilamellar liposomes

Indexed keywords

GEMCITABINE; LIPOSOME;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL DEATH; CELL VIABILITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG RELEASE; DRUG TARGETING; ENCAPSULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGHT SCATTERING; LIPOSOMAL DELIVERY; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SUPERNATANT; THYROID PAPILLARY CARCINOMA; ZETA POTENTIAL; AREA UNDER THE CURVE; CANCER CELL CULTURE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONCENTRATION RESPONSE; DRUG FORMULATION; DRUG MECHANISM; INTERNALIZATION; PH MEASUREMENT; THYROID CARCINOMA;

EID: 78349253860     PISSN: None     EISSN: 18741266     Source Type: Journal    
DOI: 10.2174/1874126601004010055     Document Type: Article

References (36)

1. Sherman, S.I. Thyroid carcinoma. Lancet, 2003, 8, 501-511.
2. Davies, L.; Welch, H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA, 2006, 295, 2164-2167.
3. Pelizzo, M.R.; Merante, B.I.; Toniato, A.; Pagetta, C.; Casal Ide, E.; Mian, C.; Rubello, D. Diagnosis, treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma. Minerva Endocrinol., 2008, 33, 359-379.
4. Filetti, S.; Bidart, J.M.; Arturi, F.; Caillou, B.; Russo, D.; Schlumberger, M. Sodium/Iodide Symporter (NIS): a key transport system in thyroid cancer cell metabolism. Eur. J. Endocrinol., 1999, 141, 443-457.
5. Schlumberger, M.; Lacroix, L.; Russo, D.; Filetti, S.; Bidart, J.M. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat. Clin. Pract. Endocrinol. Metab., 2007, 3, 260-269.
6. Arturi, F.; Russo, D.; Giuffrida, D.; Schlumberger, M.; Filetti, S. Sodium-Iodide symporter (NIS) gene expression in lymph node metastases of papillary thyroid carcinomas. Eur. J. Endocrinol, 2000, 143, 623-627.
7. Haugen, B.R. Management of the patient with progressive radioiodine non-responsive disease. Semin. Surg. Oncol., 1999, 16, 34-41.
8. Woyach, J.A.; Shah, M.H. New therapeutic advances in the management of progessive thyroid cancer. Endocr. Rel. Cancer, 2009, 16, 715-731.
9. Reddy, L.H.; Couvreur, P. Novel approaches to deliver gemcitabine to cancers. Curr. Pharm. Des., 2008, 14, 1124-1137.
10. Ringel, M.D. Molecular diagnostic tests in the diagnosis and management of thyroid carcinoma. Rev. Endocr. Metab. Disord., 2000, 1, 173-181.
11. Celano, M.; Calvagno, M.G.; Bulotta, S.; Paolino, D.; Arturi, F.; Rotiroti, D.; Filetti, S.; Fresta, M.; Russo, D. Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells. BMC Cancer, 2004, 4, 63.
12. Fritze, A.; Hens, F.; Kimpfler, A.; Schubert, R.; Peschka-Süss, R. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim. Biophys. Acta, 2006, 1758, 1633-1640.
13. Voigt, W.; Kegel, T.; Weiss, M.; Mueller, T.; Simon, H.; Schmoll, H.J. Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J. Cancer Res. Clin. Oncol., 2005, 131, 585-590.
14. Abratt, R.P. Gemcitabine hydrochloride: combination of activity and tolerability (Summary). Anticancer Drugs, 1995, 6, 63-64.
15. Immordino, M.L.; Brusa, P.; Rocco, F.; Arpicco, S.; Ceruti, M.; Cattel, L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J. Control. Release, 2004, 100, 331-346.
16. Myhren, F.; Borretzen, B.; Dalen, A.; Sandvold, M. Gemcitabine derivative. WO patent 32762, 1998.
17. Pasut, G.; Canal, F.; Dalla Via, L.; Arpicco, S.; Veronese, F. M.; Schiavon, O. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid. J. Control. Release, 2008, 127, 239-248.
18. Celia, C.; Malara, N.; Terracciano, R.; Cosco, D.; Paolino, D.; Fresta, M.; Savino, R. Liposomal delivery improves the growth-inhibitory and apoptotic activity of low doses of gemcitabine in multiple myeloma cancer cells. Nanomedicine, 2008, 4, 155-166.
19. Cosco, D.; Bulotta, A.; Ventura, M.; Celia, C.; Calimeri, T.; Perri, G.; Paolino, D.; Costa, N.; Neri, P.; Tagliaferri, P.; Tassone, P.; Fresta, M. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. Cancer Chemother. Pharmacol., 2009, 64, 1009-1020.
20. Celia, C.; Calvagno, M.G.; Paolino, D.; Bulotta, S.; Ventura, C.A.; Russo, D.; Fresta, M. Improved in vitro anti-tumoral activity, intra-cellular uptake and apoptotic induction of gemcitabine-loaded pegylated unilamellar liposomes. J. Nanosci. Nanotechnol., 2007, 8, 1-12.
21. Calvagno, M.G., Celia, C.; Paolino, D.; Cosco, D.; Iannone, M.; Castelli, F.; Doldo, P.; Fresta, M. Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes. Curr. Drug Deliv., 2007, 4, 89-101.
22. Puppin, C.; D'Aurizio, F.; D'Elia, A.V.; Cesaratto, L.; Tell, G., Russo, D.; Filetti, S.; Ferretti, E.; Tosi, E.; Mattei, T.; Pianta, A.; Pellizzari, L.; Damante, G. Effects of histone acetylation on NIS promoter and expression of thyroid-specific transcription factors. Endocrinology, 2005, 146, 3967-3974.
23. Decuzzi, P.; Causa, F.; Ferrari, M.; Netti, P.A. The effective dispersion of nanovectors within the tumor microvasculature. Ann. Biomed. Eng., 2006, 34, 633-641.
24. Berger, N.; Sachse, A.; Bender, J.; Schubert, R.; Brandl, M. Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics. Int. J. Pharm., 2001, 223, 55-68.
25. Fresta, M.; Ricci, M.; Rossi, C.; Furneri, P.M.; Puglisi, G. Antimicrobial nonapeptide leucinostatin-A: dependent effects on the physical properties of phospholipid model membranes. J. Colloid Interface Sci., 2000, 226, 222-230.
26. Diaz, R.S.; Monreal, J.; Regueiro, P.; Lucas, M. Preparation of a protein-free total brain white matter lipid fraction: characterization of liposomes. Neurosci. Res., 1992, 31, 136-145.
27. Castelli, F.; Raudino, A.; Fresta, M. A mechanistic study of the permeation kinetics through biomembrane models: gemcitabine-phospholipid bilayer interaction. J. Colloid Interface Sci., 2005, 285, 110-117.
28. Finn, S.; Smyth, P.; O'Regan, E.; Cahill, S.; Toner, M.; Timon, C.; Flavin, R.; O'Leary, J.; Sheils, O. Low-level genomic instability is a feature of papillary thyroid carcinoma: an array comparative genomic hybridization study of laser capture microdissected papillary thyroid carcinoma tumors and clonal cell lines. Arch. Pat. Lab. Med., 2007, 131, 65-73.
29. Puxeddu, E.; Durante, C.; Avenia, N.; Filetti, S.; Russo, D. Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol. Metab., 2008, 19, 138-145.
30. Griffith, D.A.; Jarvis, S.M. Nucleoside and nucleobase transport systems of mammalian cells. Biochim. Biophys. Acta, 1996, 1286, 153-181.
31. Griffiths, M.; Beaumont, N.; Yao, S.Y.; Sundaram, M.; Boumah, C.E.; Davies, A.; Kwong, F.Y.; Coe, I.; Cass, C.E.; Young, J.D.; Baldwin, S.A. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat. Med., 1997, 3, 89-93.
32. Oguri, T.; Achiwa, H.; Muramatsu, H.; Ozasa H.; Sato, S.; Shimizu, S.; Yamazaki, H.; Eimoto, T.; Ueda, R. The absence of human equilibrative nucleoside transporter 1expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett., 2007, 256, 112-119.
33. Celano, M.; Schenone, S.; Cosco, D.; Navarra, M.; Puxeddu, E.; Racanicchi, L.; Brullo, C.; Varano E.; Alcaro, S.; Ferretti, E.; Botta, G.; Filetti, S.; Fresta, M.; Botta, M.; Russo, D. Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo. Endocr. Rel. Cancer, 2008, 15, 499-510.
34. Gorumlu, G.; Kucukzeybek, Y.; Kemal-Gul, M.; Karaca, B.; Cosan-Terek, M.; Karabulut, B.; Sanli, U.A.; Akman, L.; Ozsaran, A.; Dikmen, Y.; Uslu, R. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. J. BUON., 2008, 13, 349-352.
35. Airoldi, M.; Cattel, L.; Milla, P.; Pedani, F.; Garzaro, M.; Dosio, F. Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: clinical and unexpected pharmacokinetic interactions. Anticancer Res., 2008, 28, 2519-2527.
36. Zhang, Y.; Li, A.; Wang, Z.; Han, Z.; He, J.; Ma, J. Antimetastatic activities of pegylated liposomal doxorubicin in a murine metastatic lung cancer model. J. Drug Target., 2008, 16, 679-687.